Alain Charest

Alain Charest

Auto-generated profile, based on publicly available information

Alain Charest

Cancer Research Institute, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2022 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
ACAnthos Christofides
Anthos Christofides
LSLaura Strauss
Laura Strauss
AYAlan Yeo
Alan Yeo
CCCarol Cao
Carol Cao
ACAlain Charest
Alain Charest
VBVassiliki A. Boussiotis
Vassiliki A. Boussiotis

27 May 2022 in Nature Immunology
Verified
Journal Article
Open access
PDF file
AYAlan T. Yeo
Alan T. Yeo
SRShruti Rawal
Shruti Rawal
BDBethany Delcuze
Bethany Delcuze
ACAnthos Christofides
Anthos Christofides
AAAgata Atayde
Agata Atayde
ACAl Charest
Al Charest
Glioblastoma (GBM) is an incurable primary malignant brain cancer hallmarked with a substantial protumorigenic immune component. Knowledge of the GBM immune microenvironment during tumor evolution and standard of care treatments is limited. Using single-cell transcriptomics and flow cytometry, we unveiled large-scale comprehensive longitudinal changes in immune cell composition throughout tumor progression in an epidermal growth factor receptor-driven genetic mouse GBM model. We identified subsets of proinflammatory microglia in developing GBMs and anti-inflammatory macrophages and protumorigenic myeloid-derived suppressors cells in end-stage tumors, an evolution that parallels breakdown of the blood–brain barrier and extensive growth of epidermal growth factor receptor+ GBM cells. A similar relationship was found between microglia and macrophages in patient biopsies of low-grade glioma and GBM. Temozolomide decreased the accumulation of myeloid-derived suppressor cells, whereas concomitant temozolomide irradiation increased intratumoral GranzymeB+ CD8+T cells but also increased CD4+ regulatory T cells. These results provide a comprehensive and unbiased immune cellular landscape and its evolutionary changes during GBM progression.

13 June 2025 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
KAKonstantinos Aliazis
Konstantinos Aliazis
ACAnthos Christofides
Anthos Christofides
RSRushil Shah
Rushil Shah
YYYao Yu Yeo
Yao Yu Yeo
SJSizun Jiang
Sizun Jiang
VBVassiliki A. Boussiotis
Vassiliki A. Boussiotis

15 December 2017 in Oncogene
Verified
Journal Article
Open access
PDF file
VBVassiliki A. Boussiotis
Vassiliki A. Boussiotis
ACAlain Charest
Alain Charest
Glioblastoma multiforme (GBM) is a highly malignant primary brain cancer with a dreadful overall survival and for which treatment options are limited. Recent breakthroughs in novel immune-related treatment strategies for cancer have spurred interests in usurping the power of the patient’s immune system to recognize and eliminate GBM. Here, we discuss the unique properties of GBM’s tumor microenvironment, the effects of GBM standard on care therapy on tumor-associated immune cells, and review several approaches aimed at therapeutically targeting the immune system for GBM treatment. We believe that a comprehensive understanding of the intricate micro-environmental landscape of GBM will abound into the development of novel immunotherapy strategies for GBM patients.

1 June 2019 in Cell Reports
Verified
Journal Article
Open access
AGAron Gyuris
Aron Gyuris
JNJose Navarrete-Perea
Jose Navarrete-Perea
AJAla Jo
Ala Jo
SCSimona Cristea
Simona Cristea
SZShuang Zhou
Shuang Zhou
ACAl Charest
Al Charest
Cancer extracellular vesicles (EVs) are highly heterogeneous, which impedes our understanding of their function as intercellular communication agents and biomarkers. To deconstruct this heterogeneity, we analyzed extracellular RNAs (exRNAs) and extracellular proteins (exPTNs) from size fractionation of large, medium, and small EVs and ribonucleoprotein complexes (RNPs) from mouse glioblastoma cells by RNA sequencing and quantitative proteomics. mRNA from medium-sized EVs most closely reflects the cellular transcriptome, whereas small EV exRNA is enriched in small non-coding RNAs and RNPs contain precisely processed tRNA fragments. The exPTN composition of EVs and RNPs reveals that they are closely related by vesicle type, independent of their cellular origin, and single EV analysis reveals that small EVs are less heterogeneous in their protein content than larger ones. We provide a foundation for better understanding of segregation of macromolecules in glioma EVs through a catalog of diverse exRNAs and exPTNs.

6 August 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
HJHyun Jung Jun
Hyun Jung Jun
VAVicky A. Appleman
Vicky A. Appleman
HWHua-Jun Wu
Hua-Jun Wu
CRChristopher M. Rose
Christopher M. Rose
JPJavier J. Pineda
Javier J. Pineda
ACAl Charest
Al Charest
Glioblastoma multiforme (GBM) is an aggressive primary brain cancer that includes focal amplification of PDGFRα and for which there are no effective therapies. Herein, we report the development of a genetically engineered mouse model of GBM based on autocrine, chronic stimulation of overexpressed PDGFRα, and the analysis of GBM signaling pathways using proteomics. We discover the tubulin-binding protein Stathmin1 (STMN1) as a PDGFRα phospho-regulated target, and that this mis-regulation confers sensitivity to vinblastine (VB) cytotoxicity. Treatment of PDGFRα-positive mouse and a patient-derived xenograft (PDX) GBMs with VB in mice prolongs survival and is dependent on STMN1. Our work reveals a previously unconsidered link between PDGFRα activity and STMN1, and highlight an STMN1-dependent cytotoxic effect of VB in GBM.